EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives

Yasushi Sato iD, Koichi Okamoto, Yutaka Kawano iD, Akinari Kasai, Tomoyuki Kawaguchi, Tamotsu Sagawa, Masahiro Sogabe, Hiroshi Miyamoto iD, Tetsuji Takayama

Journal of Clinical Medicine · 12.07.2023 · 12 (14) · 4646

DOI: 10.3390/jcm12144646 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.07.2023. Verfasst von Yasushi Sato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science, Tokushima 770-8503, Japa…. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer is a heterogeneous disease with diverse histological and genomic subtypes, making it difficult to demonstrate treatment efficacy in clinical trials. However, recent efforts have been made to identify molecular biomarkers with prognostic and predictive implications to better understand the broad heterogeneity of gastric cancer and develop effective targeted therapies for it. HER2 overexpression, HER2/neu amplification, MSI-H, and PD-L1+ are predictive biomarkers in gastric cancer, and a growing number of clinical trials based on novel biomarkers have demonstrated the efficacy of targeted therapies alone or in combination with conventional chemotherapy. Enrichment design clinical trials of targeted therapies against FGFR2b and claudin 18.2 have demonstrated efficacy in unresectable advanced gastric cancer. Nonetheless, it is essential to continuously validate promising molecular biomarkers and introduce them into clinical practice to optimize treatment selection and improve patient outcomes. In this review, we focused on established (PD-L1, HER2, MSI) and emerging biomarkers (FGFR2, CLDN18.2) in gastric cancer, their clinical significance, detection methods, limitations, and molecular agents that target these biomarkers.

Schlagwörter

Stichwörter der Autor:innen

FGFR2HER2MSIPD-L1claudin 18.2gastric cancertargeted therapy

Autor:innen und Institutionen

  • Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science, Tokushima 770-8503, Japan.
  • Department of Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science, Tokushima 770-8503, Japan.
  • Department of Gastroenterology, Hokkaido Cancer Center, Sapporo 060-0042, Japan.

ORCID-Profile: Yasushi Sato, Yutaka Kawano, Hiroshi Miyamoto

Zitieren

APA

Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., & Takayama, T. (2023). Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. Journal of Clinical Medicine, 12(14), 4646. https://doi.org/10.3390/jcm12144646

Vancouver

Sato Y, Okamoto K, Kawano Y, Kasai A, Kawaguchi T, Sagawa T, et al. Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. Journal of Clinical Medicine. 2023;12(14):4646. doi:10.3390/jcm12144646

BibTeX
@article{Sato2023,
  author = {Sato, Yasushi and Okamoto, Koichi and Kawano, Yutaka and Kasai, Akinari and Kawaguchi, Tomoyuki and Sagawa, Tamotsu and Sogabe, Masahiro and Miyamoto, Hiroshi and Takayama, Tetsuji},
  title = {Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {14},
  pages = {4646},
  doi = {10.3390/jcm12144646}
}
Kostenlos starten →